All In Biotech

Drug Trial Radar · NCT06364410

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Feb 3, 2025

Primary completion

Jul 8, 2027

Study completion Jul 8, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, and best dose of azenosertib in combination with trastuzumab deruxtecan in treating patients with HER2-positive gastric or gastroesophageal junction cancer and other HER2-positive solid tumors that have spread to nearby tissue or lymph nodes (locally advanced), that have spread from where it first started (primary site) to other places in the body (metastatic), or that cannot be removed by surgery (unresectable). Azenosertib is in a class of medications called kinase inhibitors. It inhibits a protein called Wee1. Inhibition of the Wee1 protein can make tumor cells more vulnerable to chemotherapy drugs, leading to tumor cell death. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Giving azenosertib in combination with trastuzumab deruxtecan may be safe, tolerable, and/or more effective in treating patients with locally advanced, metastatic, or unresectable HER2-positive gastric, gastroesophageal junction, or other solid tumors, compared to just trastuzumab deruxtecan alone.

Conditions

  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Locally Advanced Gastric Carcinoma
  • Locally Advanced Gastroesophageal Junction Adenocarcinoma
  • Locally Advanced Malignant Solid Neoplasm
  • Metastatic Gastric Carcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Gastric Carcinoma
  • Unresectable Gastroesophageal Junction Adenocarcinoma
  • Unresectable Malignant Solid Neoplasm

Interventions

  • AzenosertibDrug

    Given PO

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Trastuzumab DeruxtecanBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated doseTime frame: Up to completion of dose-escalation
  2. Recommended phase 2 doseTime frame: Up to completion of dose-escalation
  3. Incidence of dose limiting toxicities (DLTs)Time frame: Up to completion of dose-escalation
  4. Incidence of adverse events (AEs)Time frame: Up to 30 days after the last administration of study intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.